341 related articles for article (PubMed ID: 30253095)
1. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK
J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095
[TBL] [Abstract][Full Text] [Related]
2. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
[TBL] [Abstract][Full Text] [Related]
3. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
[TBL] [Abstract][Full Text] [Related]
4. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Benzo[
Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
[TBL] [Abstract][Full Text] [Related]
6. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
[TBL] [Abstract][Full Text] [Related]
7. Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.
Carlson AS; Cui H; Divakaran A; Johnson JA; Brunner RM; Pomerantz WCK; Topczewski JJ
ACS Med Chem Lett; 2019 Sep; 10(9):1296-1301. PubMed ID: 31531200
[TBL] [Abstract][Full Text] [Related]
8. A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.
Cui H; Divakaran A; Hoell ZJ; Ellingson MO; Scholtz CR; Zahid H; Johnson JA; Griffith EC; Gee CT; Lee AL; Khanal S; Shi K; Aihara H; Shah VH; Lee RE; Harki DA; Pomerantz WCK
J Med Chem; 2022 Feb; 65(3):2342-2360. PubMed ID: 35007061
[TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
11. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
12. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
[TBL] [Abstract][Full Text] [Related]
14. A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression.
Zhou Z; Li X; Liu Z; Huang L; Yao Y; Li L; Chen J; Zhang R; Zhou J; Wang L; Zhang QQ
Front Pharmacol; 2020; 11():1043. PubMed ID: 32765266
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
[TBL] [Abstract][Full Text] [Related]
16. Interfering with bromodomain epigenome readers as therapeutic option in mucoepidermoid carcinoma.
Markman RL; Webber LP; Nascimento Filho CHV; Reis LA; Vargas PA; Lopes MA; Zanella V; Martins MD; Squarize CH; Castilho RM
Cell Oncol (Dordr); 2019 Apr; 42(2):143-155. PubMed ID: 30539410
[TBL] [Abstract][Full Text] [Related]
17. Recent progress and structural analyses of domain-selective BET inhibitors.
Divakaran A; Harki DA; Pomerantz WCK
Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
[TBL] [Abstract][Full Text] [Related]
18. Segmental Isotope Labelling of an Individual Bromodomain of a Tandem Domain BRD4 Using Sortase A.
Williams FP; Milbradt AG; Embrey KJ; Bobby R
PLoS One; 2016; 11(4):e0154607. PubMed ID: 27128490
[TBL] [Abstract][Full Text] [Related]
19. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives.
Feng L; Wang G; Chen Y; He G; Liu B; Liu J; Chiang CM; Ouyang L
Med Res Rev; 2022 Mar; 42(2):710-743. PubMed ID: 34633088
[TBL] [Abstract][Full Text] [Related]
20. Development of Murine Leukemia Virus Integrase-Derived Peptides That Bind Brd4 Extra-Terminal Domain as Candidates for Suppression of Acute Myeloid Leukemia.
Xing E; Surendranathan N; Kong X; Cyberski N; Garcia JD; Cheng X; Sharma A; Li PK; Larue RC
ACS Pharmacol Transl Sci; 2021 Oct; 4(5):1628-1638. PubMed ID: 34661079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
